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Pulmonary CT and MRI Phenotypes That
Help Explain Chronic Pulmonary
Obstruction Disease Pathophysiology and
Outcomes
Eric A. Hoffman, PhD,1,2,3 David A. Lynch, MD,4 R. Graham Barr, MD,5,6
Edwin J.R. van Beek, MD,7 Grace Parraga, PhD,8,9* for the IWPFI Investigators
Pulmonary x-ray computed tomographic (CT) and magnetic resonance imaging (MRI) research and development has
been motivated, in part, by the quest to subphenotype common chronic lung diseases such as chronic obstructive pul-
monary disease (COPD). For thoracic CT and MRI, the main COPD research tools, disease biomarkers are being vali-
dated that go beyond anatomy and structure to include pulmonary functional measurements such as regional
ventilation, perfusion, and inflammation. In addition, there has also been a drive to improve spatial and contrast resolu-
tion while at the same time reducing or eliminating radiation exposure. Therefore, this review focuses on our evolving
understanding of patient-relevant and clinically important COPD endpoints and how current and emerging MRI and CT
tools and measurements may be exploited for their identification, quantification, and utilization. Since reviews of the
imaging physics of pulmonary CT and MRI and reviews of other COPD imaging methods were previously published and
well-summarized, we focus on the current clinical challenges in COPD and the potential of newly emerging MR and CT
imaging measurements to address them. Here we summarize MRI and CT imaging methods and their clinical translation
for generating reproducible and sensitive measurements of COPD related to pulmonary ventilation and perfusion as
well as parenchyma morphology. The key clinical problems in COPD provide an important framework in which pulmo-
nary imaging needs to rapidly move in order to address the staggering burden, costs, as well as the mortality and mor-
bidity associated with COPD.
J. MAGN. RESON. IMAGING 2016;43:544–557.
Copd Measurements and Endpoints are
Urgently Needed
Despite decades of research, therapies that modifychronic obstructive pulmonary disease (COPD) pro-
gression or mortality are lacking.1 Despite considerable
efforts to discover and develop new COPD interventions,
progress has been slow. This is in large part due to limited
and suboptimal patient phenotyping that relies on spirome-
try measurements made at the mouth that cannot account
for the regional and intersubject variability of COPD.
Moreover, while COPD is still diagnosed and classified on
the basis of symptoms related to the presence of persistent
airflow limitation,1 these measurements correlate weakly
with important clinical outcomes.2
A wide variety of imaging methods may be used to study
the pulmonary system, including those that rely on tissue
absorption of x-ray radiation (chest x-ray and computed
tomography [CT]), radiofrequency stimulation (magnetic res-
onance imaging [MRI]), or signals generated from injected or
inhaled radioactive particles (simple gamma emission projec-
tion imaging, single photon emission tomography [SPECT]
and positron emission tomography [PET]) and inhaled or
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injected contrast agents. New insights into the basis for disease
initiation and progression using these methods have the
potential to break through the current conundrum, which is
the fact that image acquisition and analysis tools are slow to
be adopted because of a lack of meaningful interventions and
yet the interventions are slow in coming because of a lack of
understanding disease mechanisms and etiology. Therefore, as
shown in Fig. 1, we frame this review of CT and MRI meas-
urements and phenotypes as potential solutions to the follow-
ing major COPD problems: 1) COPD treatments are
required that improve outcomes, not just symptoms; 2) a bet-
ter understanding of COPD disease onset and mechanisms is
urgently required in order to better design drugs targeted at
underlying pathophysiology; 3) more sensitive measurements
are required to better understand the links between ventila-
tion, perfusion, and inflammation; and 4) better predictive
measurements of COPD exacerbations and progression are
critically needed. Here we summarize and compare MRI and
CT tools and measurements of COPD because of their near-
universal availability that makes their use in COPD multicen-
ter clinical trials and COPD patient care both practical and
timely. Taken together, MRI and CTmethods provide a way
to identify the underlying pathologies associated with COPD
and previous work has been summarized and previously
reviewed.3–5
Pulmonary CT Measurements of Copd
CT Structural Measurements and Phenotypes
Computer-based methods6–9 for the objective quantitation of
CT images are increasingly used in multicenter studies10–15
that aim to interrogate phenotype–genotype linkages and
identify intermediary endpoints for the assessment of poten-
tial interventions. A cornerstone of this approach is the CT
lung tissue attenuation or density mask that provides a way to
estimate regional COPD-related emphysema. By empirically
defining regional emphysematous lung using selected thresh-
old tissue attenuation measurements (Hounsfield Unit [HU])
at full inspiration (total lung capacity [TLC]), one can count
the number of voxels in the whole lung and express this mea-
sure. In this way, the percent of voxels reflecting emphysema
can be expressed relative to the total volume of the lung or
lung region.16–23 The CT density mask is particularly useful
in classifying mild/moderate and severe emphysema24,25 and
has been used in the National Emphysema Treatment Trial
(NETT) to identify subgroups of patients who show benefit
from lung volume reduction surgery.26 In the left panel of Fig.
2 (using Apollo software provided by VIDA Diagnostics, Cor-
alville, IA), the spatially heterogeneous distribution of emphy-
sema, shown in spheres and regional clustering (sphere size), is
shown by lung lobe. Similarly, a density mask may be used on
the expiratory dataset (residual volume [RV] or functional
residual capacity [FRC]) to identify regions of air trapping as
shown in the middle panel of Fig. 2. In both the inspiratory
and expiratory images, airways may also be segmented and
labeled9,27,28 using commercially available software such that
relationships can be determined between the airway path,
airway remodeling features, and parenchymal destruction or
peripheral airway closure. CT-based density metrics have been
used in numerous large-scale studies,12–15 producing a wealth
of literature over the past several years. These measures have
identified correspondence of quantitative CT measures of
emphysema and air trapping to, for example: genotypes,29,30
FIGURE 1: Current COPD challenges. Three distinct COPD phases are outlined in schematic: 1) Early disease when patients are
asymptomatic, clinical measurements typically do not reflect disease but imaging measurements provide evidence of mild emphy-
sema, airways disease, perfusion heterogeneity, LV filling defects, etc. 2) Mild-moderate COPD as patients become symptomatic,
clinical measurements are modestly abnormal while imaging measurements can be markedly abnormal revealing regional disease,
LV filling defects can continue to worsen, comorbidities can begin to appear including aortic aneurysms, coronary disease, lung
nodules, and osteoporosis. 3) Severe COPD with patients reporting severe symptoms and activity impairment, clinical measure-
ments of airflow limitation, diffusing capacity of carbon monoxide, and gas trapping are markedly abnormal and yet patients still
can be differentiated into those with predominantly airway or predominantly parenchymal disease with marked differences in the
distribution of parenchymal destruction.
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left ventricular (LV) filling,31 physiologic measures,32,33 envi-
ronmental smoke exposure in childhood as a risk factor for
emphysema,34 predictors of bronchoreversibility,35 association
of cigarette smoking with subclinical disease,36 and trapped
gas in severe asthma.37 It is also important to note that in
addition to tissue attenuation or density masks, texture analy-
ses may be employed to evaluate clusters of emphysema38
such as estimated using low attenuating clusters. Image analy-
sis methods based on such local feature patterns provide a way
to objectively differentiate between these subtypes and some
of these methods have better classification rates than expert
radiologists.39 So-called low attenuation clusters are visually
obvious, correlating with histopathology measurements40 and
more closely reflecting scoring performed by a radiologist.41
However, CT quantification of the lung parenchyma is
also challenging. Scanner miscalibration, inconsistent use of
reconstruction kernels, differences in reconstruction algo-
rithms between manufacturers, and poor coaching of the
patient to the targeted lung volume can result in measure-
ment variability.42–45 Accurate, quantitative CT requires
image acquisition consistency,46 and even then, subject age,
sex, race/ethnicity, and height influence the normal range of
these measures (similar to lung function) as does weight.47
Current smoking status has a large and paradoxical effect on
these measures,47 making precise measurements of smoking
status (eg, cotinine or other objective measure) important in
longitudinal studies. Reference equations for both percent
emphysema and total lung volume on CT are now available
to account for most of these differences.47 The limitations
due to concerns of radiation dose are being addressed with
recent advances in CT technologies, including improve-
ments in the x-ray tube, detector technology, adaptive expo-
sure,48,49 and iterative image reconstruction,50–54 leading to
clinically adequate image quality with sub-mSv doses.48,55
Finally, despite considerable successes using quantitative CT
to assess the presence and distribution of emphysema and
airway wall remodeling,56–61 critical underlying differences
among disease subpopulations continue to emerge. For
example, in an apparently discordant result, spatially
matched airway segmentation demonstrated that airway
walls may become thinner rather than thicker in COPD,
leaving open the possibility that airway wall remodeling
may itself have multiple phenotypes.9
Functional CT Measurements and Phenotypes
PULMONARY CT VASCULAR OR PERFUSION. It has
long been thought that a better understanding of the patho-
logic response to inflammation in COPD and asthma will be
important for the design of new therapies. What is well under-
stood is that in response to noxious particles and gases in ciga-
rette smoke, the lung reacts by recruiting inflammatory cells.
Pulmonary vascular changes, including thickening of the ves-
sel walls, have been characterized early in the history of
COPD.62,63 More recently it was observed that in the pres-
ence of inflammation there is an enhanced delivery of progen-
itor cells to the lung.64,65 Remy-Jardin et al66 recently
observed an increased propensity for the lung to develop
emphysema in regions of suspected inflammatory processes as
FIGURE 2: CT measurements: Threshold-based evaluation of
the extent and distribution of emphysema at full inspiration
(top panel), amount and air trapping at expiration to functional
residual capacity (FRC) or residual volume (RV) (middle panels),
airway geometry assessed in conjunction with distribution pat-
terns of emphysema and air trapping (middle panels), vascular
anatomy (total pulmonary vascular volume and total pulmonary
arterial volume assessed from full inspiratory noncontrast-
enhanced CT scans (bottom panel). Color-coding differentiates
between lung lobes.
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defined by ill-defined ground-glass opacities and micronod-
ules. In more than half of smokers, the inflammatory process
was able to resolve itself with repair and maintenance of nor-
mal parenchymal anatomy and function. For the remainder
(30–45% of smokers) there was parenchymal destruction.
There is evidence in the literature suggesting that in humans
and animals, hypoxic pulmonary vasoconstriction (HPV) is
normally blocked in the presence of inflammation.25,67–69 For
example, Alford et al70 demonstrated that smokers with nor-
mal pulmonary function, but small visibly obvious signs of
localized, apical centrilobular emphysema, have an increase in
coefficient of variation (CV) of CT-based regional pulmonary
blood flow (PBF) and mean transit time (MTT), supporting a
hypothesis that one etiology of smoking-associated emphy-
sema may be failure to maintain PBF to inflamed lung
regions. Recent work published together with an associated
editorial31,71 also demonstrated and discussed the strong rela-
tionship between impaired LV filling and percent emphysema
in a group of nonsmokers, exsmokers, and current smokers.
The correlation between impaired LV filling with emphysema
was greatest in current smokers compared with previous
smokers, consistent with the notion that the inflammatory
effects of smoking may determine this effect rather than
emphysema alone.
With the observation that pulmonary perfusion heter-
ogeneity may serve as a biomarker in smokers susceptible to
centrilobular emphysema,70 it has been hypothesized that
the lung normally inhibits HPV in the presence of inflam-
mation. Conversely, in patients unable to block HPV in
inflamed lung regions, perfusion is reduced, thus prolonging
inflammation and limiting repair mechanisms. With the use
of single-breath methods in conjunction with dual energy
CT, efforts have been directed towards maintaining sensitiv-
ity to increased perfusion heterogeneity while simplifying
imaging methodologies.
Dual-energy CT (DECT) provides a way to double
the temporal resolution of CT, making it possible to image
the entire lung field with a 0.62-mm slice thickness in 0.6
seconds. By having two x-ray guns together with two sets of
detector rows, both capable of acquiring 128 slices of image
data, there is now the possibility of DECT which allows for
sensitive discrimination between tissue types and contrast
agents such as iodine for perfusion and xenon (Xe) for ven-
tilation. At two different peak kilo-voltages (kVp), the
reconstructed CT densities for iodine or Xe are shifted sig-
nificantly between the two resultant image datasets, but the
body tissues are not. Thus, because the two image sets were
acquired simultaneously, assuring alignment, with a modi-
fied form of image subtraction (material decomposition), it
is possible to assess perfused blood volume or regional venti-
lation, respectively. For regional assessment of perfused
blood volume, when blood is equilibrated with a concentra-
tion of iodine (or gadolinium) through the slow infusion of
contrast agent, an image of iodine (or gadolinium) can be
directly related to regional blood volume.
Other studies have demonstrated the equivalency of
perfused blood volume (PBV), as assessed by DECT, and
true perfusion. PBV and PBF likely reflect one another
because peripheral vascular beds dilate and capillary beds are
recruited with increased PBF. PBV may be evaluated using
DECT during a slow infusion of x-ray contrast. As shown
in Fig. 3, modified72 from a report on interventions
performed in pigs, regional perfusion (color-coded from red
to blue as percent of total perfused blood volume or total
perfusion) was perturbed either by incrementally pulling
back a balloon catheter placed in a pulmonary artery or by
imaging the lung at various static inflation pressures which
effectively reduces perfusion in the nondependent lung
regions.72 Under all conditions, PBF maps and PBV maps
are strikingly similar and a strong relationship for PBF and
PBV heterogeneity was also demonstrated.
PULMONARY CT VENTILATION. Xe gas regional wash-in
and washout kinetic studies were also explored using CT
imaging73–75 and these methods have been translated clini-
cal studies.76–82 Importantly, with the more recent develop-
ment of DECT, it is possible to simplify the assessment of
regional ventilation via use of single-breath methods. As
shown in Fig. 4, by adjusting Xe inhalation of a Xe/O2 gas
mixture, gas flow to the central airways may be monitored
and compared with gas flow to the parenchyma. As shown
in Fig. 4, left panel, the central airway tree is identified by
having the subject inhale to TLC, exhale the central dead
space volume, and reinhale the same volume of a Xe gas
mixture. This leaves just the central airways filled with Xe
gas. In the right panel, results are shown from a single inha-
lation of a Xe gas mixture. It was also demonstrated that
with a slow inhalation of Xe gas mixtures, geometry, and
gas density influence or dominate gas distribution causing
increased ventilation heterogeneity, while with a rapid inspi-
ration, ventilation is more homogeneous.83 Furthermore,
the gravity-driven distribution of Xe gas can be eliminated
by mixing Xe with helium (He), likely due to the change in
the gas density mixture. Another contrast gas agent, krypton
(Kr), while less radiodense than Xe,84,85 has no anesthetic
effects. As multispectral CT technologies, including photon
counting CT,86–88 evolve, it is expected that sensitivity to
Kr gas contrast will improve, making it a potential transla-
tional/clinical method.
As an alternative to inhaled contrast agents, recent stud-
ies89,90 have shown that regional measures of lung ventilation
can be assessed using CT images acquired at different volumes
without the need for inhaled contrast agents. A two-lung vol-
ume (TLC or full inspiration and RVor full expiration) proto-
col has been standardized as part of “SPIROMICS”,13 a CT
protocol that obtains isotropic submillimeter images of the
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entire lungs at TLC and RV. Using this protocol together with
advanced image registration methods,90–95 regional maps of
lung ventilation can be obtained at spatial resolutions close to
the size of a pulmonary acinus. Image matching of an inspira-
tory/expiratory lung image pair has also been employed7 to
help differentiate air trapping from emphysema. Functional
measurements may be directly generated from expiratory
CT96,97 or a combination of inspiratory and expiratory CT,
including those generated using parametric response maps.7
All of these important approaches have the potential to test
FIGURE 4: DECT scans of the airway tree (left) and lung parenchyma (right) of an anesthetized pig. For the scan in the left panel,
the lung was inflated to 25 cmH2O airway pressure using room air. An amount of air approximately equal in volume to the central
airway tree was removed and replaced with xenon gas. This provided a way to identify the central airway tree without the use of
more conventional airway segmentation methods. In the right panel, the lungs were inflated from functional residual capacity to
total lung capacity via a gas mixture of 80% xenon and 20% oxygen. Material decomposition image processing was used to
generate an image representing the regional distribution of the inhaled xenon gas.
FIGURE 3: Gray-scale (top row), PBV (middle row), and PBF (lower row) MDCT scans (Columns 1–3). Color map comparison of CT-
derived PBF and PBV from pig imaged at three different lung volumes, used to achieve a range of pulmonary perfusion values
(Column 4). Color map comparison of CT-derived PBF (dynamic axial scanning) and PBV (dual energy spiral scanning) from pig
studied with a balloon partially inflated in a left lower lobe pulmonary artery. Color coding is the same for each condition: percent
of total PBV or PBV with low values in blue and high values in red. Modified from Ref. 72.
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the hypotheses generated using micro-CT98 about the patho-
logical mechanisms that accompany the earliest airway and
parenchyma changes in COPD.
There is well-developed software commercially avail-
able for evaluating the relationship of airway microstruc-
tural abnormalities with ventilation and emerging software
tools are now being developed to probe the geometry of
the pulmonary arterial and venous trees and vascular–
structure function relationships.99–101 The extracted pul-
monary vascular tree from a noncontrast inspiratory
MDCT volume of the lung is shown in the right panel of
Fig. 2, and the volume of this combined arterial and
venous tree, the total pulmonary vascular volume
(TPVV), has been developed using methods that segment
the arterial tree101. The cross-sectional area of the pulmo-
nary trunk relative to the aorta has been shown102 to cor-
relate with acute exacerbations in COPD patients and
TPVV (normalized to total lung volume) is currently
being used as an upstream marker of downstream endo-
thelial dysfunction103.
Pulmonary MRI Measurements of COPD
Conventional 1H MRI Structural and Functional
Phenotypes
As pulmonary CT continues to advance with new capabil-
ities and lower radiation doses, pulmonary MRI has also
advanced to provide complementary tools for the quantita-
tive evaluation of lung structure and function. However,
pulmonary MRI using conventional hardware platforms
(1H methods) is very technically challenging and therefore,
currently its clinical use has been limited. These technical
demands stem from the inherently low pulmonary 1H
abundance and corresponding low 1H signal that can be
measured using conventional MRI approaches. Further-
more, the multitude of lung air–tissue interfaces generate
significant magnetic field distortions or susceptibility arti-
facts, further diminishing pulmonary 1H MRI signal. For
these reasons, and until recently, the major applications of
conventional pulmonary 1H MRI included intravenous
contrast agents to evaluate pulmonary blood flow and ves-
sel hemodynamics.104 Methods have also been devised that
combine relaxation signals and intravenous contrast that
provide a way to differentiate inflammation105, smooth
muscle remodeling, edema, and mucus deposition.104,105
Taken together, these methods provide a way to identify
the underlying pathologies associated with COPD. How-
ever, because signal intensity is generally very low using 1H
MRI, careful calibration with other organs in the same
field of view is required. In addition, because gravity-
dependent changes occur, signal averaging over time may
not provide physiologically relevant information in the
dependent lung regions, where atelectasis may occur in
minutes while supine.
Another way to address these challenges is to reduce the
time (echo time [TE]) required to acquire the pulmonary MR
signal. As shown in Fig. 5, conventional, ultrashort TE (UTE)
pulse sequences, as suggested two decades ago106, significantly
improve pulmonary MR signal so that emphysematous
regions can be identified and quantified, based on the differ-
ence between tissue-poor emphysematous bullae and more
normal parenchyma. So-called ultrashort-echo or zero echo
time MRI methods help address the inherent challenges of
low tissue and 1H density107 by minimizing the effects of
rapid MR signal decay. The relationship between MRI signal
intensity and tissue density108, as previously shown for pul-
monary CT, is clearly important for further development of
the method. The first studies employing UTE methods
reported that the tissue density was related to MR signal109
and T2*. UTE MRI was also used to measure signal intensity
and T2* in emphysema
110 and showed good correlations with
histological measurements, while T2* correlated with pulmo-
nary function measurements111 and pulmonary signal inten-
sity was related to tissue density, pulmonary function, and CT
density measurements.108 Very recently, methods have been
developed that exploit optimized112 and so-called zero echo
time (ZTE)113 approaches and this has resulted in excellent
MR image quality and signal in pulmonary images that is very
similar to CT. Another method for measuring regional lung
function involves using inhaled oxygen in combination with
1H MRI114 and this exploits the alteration of lung tissue 1H
relaxation times by molecular O2. In this manner, wash-in or
difference maps can be generated by using the inherent signal
differences that stem from breathing room air and pure
O2. While pulmonary ventilation is reflected by O2 wash-in
maps, the alveolar-capillary transfer may be reflected by
the O2-enhancement ratio.
115 Like all 1H-based MRI,
O2-enhanced MRI is limited by the weak proton signal and
the fact that O2-enhanced measurements still require histo-
pathological validation. In fact, for all MRI measurements of
COPD, validation of the pathologies directly or indirectly
measured is still pending.
To tackle the challenge of very low pulmonary 1H signal
intensity, Bauman and colleagues116–118 proposed another
ingenious approach that relies on MRI signal oscillations that
occur with the differences in lung volume during normal tidal
breathing. It was hypothesized that the 1H MRI signal oscilla-
tions during breathing could be employed to generate both
ventilation and perfusion images. They developed a way119
using Fourier decomposition (FD) of oscillating 1H signal
intensity120 related to the compression and expansion of the
lung parenchyma and blood flow121 to generate pulmonary
ventilation and/or perfusion measurements. Importantly, this
method was recently shown in COPD subjects with emphy-
sema122 and contrast can be generated using static volumetric
1H MRI methods123. Figure 5 shows very recent examples of
FD of pulmonary magnetic resonance imaging (FDMRI) in
Hoffman et al.: CT and MRI of COPD
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COPD subjects across GOLD grades and excellent compari-
sons were also shown in animal studies124. FDMRI exploits
free-breathing 1H MRI and nonrigid registration to generate
ventilation images. Importantly, although image registration
and analysis is complex, and again dependent on weak 1H
MRI contrast, this approach does not depend on inhaled gas
or injected contrast agents, and therefore there is strong
potential for clinical translation. Again, a more complete vali-
dation still needs to be undertaken.
Inhaled 19F and Hyperpolarized 129Xe/ 3He MRI
Structural and Functional Phenotypes
Similar to FD and O2-enhanced
1H MRI methods, MRI
using inhaled 19F gas (after multiple breaths of perfluoro-
propane mixed with oxygen), or hyperpolarized noble gases
such as 3He and 129Xe (after a single breath mixed with
4He or N2), provides a way to visualize pulmonary ventila-
tion by taking advantage of high gas density in the lung.
For inhaled 3He and 129Xe, increased nuclear polarization
generates ventilation images of the airways and airspaces and
to measure apparent diffusion coefficients that estimate gas
displacement. For 129Xe, similar to Xe-CT methods, the
fractional solubility of Xe gas in biological tissues125 has
additional applications for measuring gas exchange, alveolar
surface area, and perfusion. For all three gases, the nuclear
proton provides the MRI signal. In the case of 19F, MR sig-
nal is inherently strong because of the high gyromagnetic
ratio of 19F such that extra polarization (and polarization
FIGURE 5: MRI measurements of COPD for different GOLD stages including: emphysema (ADC, 1H MRI signal intensity), and ven-
tilation (3He MRI and FDMRI).
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equipment) is not required. For both 3He and 129Xe,
however, nuclear polarization is achieved126,127 using laser
polarization equipment. As shown in Fig. 5, 3He and 129Xe
MRI provide superior signal-to-noise ratio ventilation
images in COPD subjects, and typically, image quality using
3He MRI is the greatest compared with polarized 129Xe and
unpolarized 19F due to larger gyromagnetic ratio and high
polarization rates for 3He. For these reasons, currently 3He
MRI is most commonly used in research even though the
global quantities of 3He are very limited and expensive.
Although experience with 129Xe and 19F is still lim-
ited,128,129 these inhaled gas MRI methods provide the
strongest translational potential because of the relative abun-
dance and low cost of these gases.
Notwithstanding these challenges, recent acute therapy
studies in COPD post-salbutamol130 and post-COPD
exacerbation therapy requiring hospitalization131 show the
potential for inhaled gas MRI ventilation defect measure-
ments to represent the subtle (post-exacerbation) and not so
subtle (post-salbutamol) ventilation improvements after ther-
apy. It is important to note that the visibly obvious and stat-
istically significant improvements in ventilation in these
cases were not related to FEV1 improvements. In addition,
in a number of these previous COPD studies132, and as
shown in Fig. 6 ventilation measured using MRI was
directly related to CT-derived measurements of abnormally
remodeled airways and emphysema. Importantly, previous
work also showed the relationship of ventilation
FIGURE 6: MR ventilation imaging reflecting the effects of both emphysema (slow-filling units) and airways disease (airway
obstruction)—a unique predictor of COPD exacerbations in mild disease.
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abnormalities with subclinical disease in smokers with nor-
mal lung function133. Moreover, regional ventilation wor-
sening in COPD has been measured over a follow-up
period of 2 years134 even in patients with no change in
FEV1. The Polarized Helium Imaging of the Lung (PHIL)
Study was performed in three European centers in 122
COPD patients and is the largest COPD MRI-CT multi-
center comparison study completed to date132. This impor-
tant study showed the potential for COPD biomarkers
stemming from a comprehensive, prospectively planned,
multicenter and multimodality imaging approach. Another
innovative example135 showed the potential of ventilation
MRI to interrogate the role of regional collateral ventilation
in COPD patients with bullous emphysema. Finally, MRI
measurements of ventilation in mild and moderate patients
(GOLD I/II COPD)136 were also predictive of COPD exac-
erbation requiring hospital care, and in these patients previ-
ous exacerbation and FEV1 were not.
For all inhaled gas MRI methods, diffusion due to ran-
dom Brownian motion within the lung airways and airspaces
can be measured using diffusion-weighted imaging similar to
that used in conventional MRI137. 3He or 129Xe diffusion-
weighted methods provide measurements of parenchyma
microstructures, including the alveoli and acini that define the
boundaries of the fundamental units for gas exchange138. The
apparent diffusion coefficient (ADC) map provides quantita-
tive regional airspace measurements information that is in
agreement with the presence of emphysematous dam-
age.139,140 Such measurements are consistent with alveolar
changes related to differences in lung volumes141 gravitational
dependence141–143 and aging.144 Previous COPD studies have
shown that ADC correlates with pulmonary func-
tion,142,145,146 histological measurements of lung surface
area,147 and is highly reproducible in COPD,141 while sensi-
tive to subclinical disease148,149 and disease progression.150
Novel approaches have also been used to measure diffusion in
longer time frames,151 providing a way to generate informa-
tion about acinar duct and airway connectivities, including
communication and collateral ventilation.152,153 Long-range
ADC appears to be more than twice as sensitive to parenchy-
mal differences associated with COPD than short-range
ADC.154–156 Unfortunately, this important information has
not yet been exploited in clinical research studies.
Gadolinium-Enhanced MRI Pulmonary Perfusion
Phenotypes
Given the relative lack of 1H signal in the lung using con-
ventional approaches, gadolinium-enhanced imaging of first-
pass pulmonary perfusion provides sensitive and relatively
reproducible measurements of signal increase and its change
over time (slope). Fourier transformation of the signal
change allows for the assessment of pulmonary blood flow,
mean transit time, and pulmonary blood volume. These
measures can be attained over the whole lung or the lung
periphery in order to evaluate microvascular perfu-
sion.157–159 Pulmonary perfusion deficits were observed
more frequently in COPD patients as compared to healthy
volunteers; the largest study to date noted largely dimin-
ished pulmonary microvascular blood flow in mild to severe
COPD with strong spatial correlations in severe disease to
centrilobular and panlobular emphysema160.
Conclusion
As summarized in Table 1, pulmonary CT and MRI are on
the threshold of providing regional, noninvasive measure-
ments of ventilation, perfusion, and parenchymal destruc-
tion as intermediate endpoints of COPD. However, whereas
pulmonary CT measurements have been evaluated in
COPDGene,12 ECLIPSE,14 MESA Lung161, CanCOLD,15
and SPIROMICS,13 and cardiac MRI has been utilized in
over 5000 participants in MESA, pulmonary MRI has not
been exploited in large-scale studies. There are many reasons
for this, even though pulmonary MRI is rapid, well-
tolerated, and radiation-free, so it serves as an ideal platform
for serial and longitudinal evaluations in patients. More
TABLE 1. MRI and CT COPD Phenotypes
Imaging biomarkers of COPD
Airways disease Emphysema Perfusion abnormalities
CT Lumen area
Wall area %
Pi10
PRM-gas trapping
Xe gas ventilation
Low attenuating clusters
Low attenuating area
RA950
RA856
PRM-emphysema
Total pulmonary vascular
volume
Iodine perfusion
MRI Ventilation defect percent
Percent ventilated volume
ADC Gadolinium perfusion
Xe perfusion/diffusion
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widespread use of all imaging biomarkers has been limited
for a number of key reasons, including: 1) lack of support
to harmonize image acquisition software; 2) universally
available image analysis software; 3) regulatory boundaries
for emerging approaches; and 4) historically weak links
between respiratory and radiology clinical programs. Not-
withstanding these issues, as shown in Fig. 6 CT and MRI
measurements of COPD are being developed to provide a
better understanding of disease onset, develop COPD treat-
ments that improve outcomes, and to provide better predic-
tive measurements of COPD exacerbations and progression.
The unique and complementary ability of both MRI
and CT to measure disease morphological and functional
consequences and explore mechanisms of disease pathophys-
iology has not yet translated to improved COPD patient
care. In COPD, there is an increasing recognition that dif-
ferent phenotypes exist162–164 and that these patient groups
may have different responses to therapy. Moreover, as thera-
pies become more targeted and patient-specific, imaging will
likely be one of the only ways to verify response and efficacy
for an individual patient or group of patients. This will
require imaging to become more quantitative, sensitive, and
accessible to justify its current cost and complexity.
Although the risks related to tobacco smoking will decrease
over time in the developed world, as the world becomes
more industrialized and polluted, and smoking habits
change in the developing world, respiratory illnesses will
continue to increase in prevalence, morbidity, and overall
mortality. It is in this clinical context that development and
appropriate utilization of pulmonary MRI and CT remain
critically important.
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